Abstract:As a major drug target for anti-inflammatory therapy, the glucocorticoid receptor (GR) regulates a wide range of physiological processes through transactivation (TA) or transrepression. GR TA is involved in many adverse effects of GR-targeting drugs, and therefore, the discovery of novel GR ligands with lower TA activity and longer residence time is quite urgent. Undoubtedly, understanding the ligand dissociation mechanisms and the structural basis of the TA regulation is crucial for the development of novel GR-targeting drugs. Here, we used random accelerated molecular dynamics (RAMD) and funnel metadynamics (FM) simulations to explore the dissociation mechanisms of 5 classic glucocorticoids and 6 nonsteroidal GR ligands. Multiple ligand dissociation pathways were discovered. The classic glucocorticoids exhibit a strong preference for Path I, and most nonsteroidal ligands tend to dissociate along mixed pathways. We also find that the distinct unbinding preferences for AZD2906 and AZD9567, two representative nonsteroidal ligands with similar scaffolds but different TA activities, are primarily determined by their different polar interactions with the surrounding residues. Notably, the binding of AZD9567 poses a substantial impact on the conformation of the GR homodimer interface, which provides a valuable clue to understand the mechanisms of the TA-related side effects induced by the adjustments of the homodimerization process. These findings are critical for the structure-based rational design of novel GR ligands with more potent anti-inflammatory potency and reduced side effects.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jcim.1c00150.Table S1, structural clustering information on important states characterized by FM simulations; Figure S1, static binding poses of ligands; Figure S2, FESs along Z axis of funnel region of four trajectories: (A) AZD2906 dissociates through Path I, (B) AZD2906 dissociates through Path II, (C) AZD9567 dissociates through Path I, and (D) AZD9567 dissociates through Path II; Figures S3–S6, binding process of GR-AZD2906 and GR-AZD9567 obtained by FM simulations; Figure S7, funnel-shaped FESs of four trajectories: (A) AZD2906-Path I, (B) AZD9567-Path I, (C) AZD2906-Path II, and (D) AZD9567-Path II; Figure S8, conformation of dimer interface (GR-AZD9567) at 0, 1, 2, and 3 μs in three unbiased replicas; Figure S9, conformation of dimer interface (GR-AZD2906) at 0, 1, 2, and 3 μs in three unbiased replicas; and Figure S10, local interaction of p-phenyl fluoride and its substituent heterocycles in series of ligands reported by Ripa et al.: (A) compound 12, (B) compound 13, (C) compound 14, (D) compound 15 (AZD9567), (E) compound 16, (F) compound 17, (G) compound 18, and (H) AZD2906 (PDF)Input files for FM simulations and NAMD (ZIP)This article has not yet been cited by other publications.

Discovery and Optimization of N -Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators

Discovery of novel non-steroidal selective glucocorticoid receptor modulators by structure- and IGN-based virtual screening, structural optimization, and biological evaluation

Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Protopanaxadiol Derivative: A Plant Origin of Novel Selective Glucocorticoid Receptor Modulator with Anti-inflammatory Effect

Discovery of Novel N -Sulfonamide-tetrahydroquinolines as Potent Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists for the Treatment of Psoriasis

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Discovery of novel and potent sulfonamide derivatives as orally available drug for psoriasis

A ligand-specific kinetic switch regulates glucocorticoid receptor trafficking and function

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Discovery Of 2-Alkyl-1-Arylsulfonylprolinamides As 11 Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors

Impact of atropisomerism on a non-steroidal glucocorticoid receptor agonist

Channel Expansion in the Ligand-Binding Domain of the Glucocorticoid Receptor Contributes to the Activity of Highly Potent Glucocorticoid Analogues

Molecular View on the Dissociation Pathways and Transactivation Regulation Mechanism of Nonsteroidal GR Ligands

Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release

Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone Derivatives As Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists.

Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists

Discovery of Novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides As Potent RORγt Inhibitors

A plant‐derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy